Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

Big Pharma firm Pfizer eyes potential sale of its hospital drugs unit

The news: Pfizer tapped Goldman Sachs to gauge potential buyer interest in its hospital drugs unit, Pfizer Hospital. The decision to sell the unit isn’t final and the drugmaker could choose to keep it.

For context, Pfizer Hospital was formed after Pfizer purchased Hospira for $17 billion in 2015. Its portfolio includes sterile injectables like antibiotic brand Zithromax, immune globulin treatment Panzyga, and the steroid Medrol.

Pfizer Hospital has been plagued by recalls in recent years, with reports of leaking products and the potential presence of glass particulates in vials and syringes of certain medications, per FiercePharma.

What’s driving the news? Activist investor Starboard Value recently took a nearly $1 billion stake in Pfizer with aims of turning its performance around.

  • The drugmaker’s market cap has plummeted from about $290 billion in late 2022 to just over $150 billion as of the time of writing.
  • Starboard recently called on Pfizer’s board to “hold management accountable” and scolded the drugmaker’s leadership for what it perceives as approximately $20 billion to $60 billion in value destruction since 2019. It pointed to inadequate returns on R&D investments and a $70 billion M&A spree.

You've read 0 of 2 free articles this month.

Create an account for uninterrupted access to select articles.
Create a Free Account